Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy.

Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J, Lin L, Xie Q, Bao S, Wang H.

Oncotarget. 2016 Sep 6;7(36):58553-58562. doi: 10.18632/oncotarget.10155.

2.

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.

Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, Bourlière M, Riachi G, Zarski JP, Cadranel JF, Tilliet V, Stern C, Pétour P, Libert O, Consoli SM, Larrey D.

Dig Dis Sci. 2016 Oct;61(10):3072-83. doi: 10.1007/s10620-015-4027-8.

3.

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH.

Hepatol Int. 2016 Jan;10(1):1-98. doi: 10.1007/s12072-015-9675-4.

4.

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.

Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV.

Adv Ther. 2015 Aug;32(8):727-41. doi: 10.1007/s12325-015-0232-2.

5.

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.

Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F.

World J Hepatol. 2015 May 18;7(8):1097-104. doi: 10.4254/wjh.v7.i8.1097. Review.

6.

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.

Wang Y, Liu S, Chen Y, Zheng S, Zhou L, Lu F, Duan Z.

Int J Med Sci. 2015 May 15;12(5):416-22. doi: 10.7150/ijms.11687.

7.

HIV through the looking glass: insights derived from Hepatitis B.

Rivera MM, Soza A, Jazwinski A, Mi L, Kleiner DE, Zhao X, Zuber C, Brust D, Hsu E, Simpson J, Hoofnagle JH, Heller T.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):123-7. doi: 10.1097/QAI.0000000000000415.

8.

Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy.

Moon JC, Kim SH, Kim IH, Lee CH, Kim SW, Lee SO, Lee ST, Kim DG.

Gut Liver. 2015 May 23;9(3):395-404. doi: 10.5009/gnl14170.

9.

Recent advances in micro/nanotechnologies for global control of hepatitis B infection.

Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U.

Biotechnol Adv. 2015 Jan-Feb;33(1):178-90. doi: 10.1016/j.biotechadv.2014.11.003. Review.

10.

Hepatitis B viral load affects prognosis of hepatocellular carcinoma.

Yu SJ, Kim YJ.

World J Gastroenterol. 2014 Sep 14;20(34):12039-44. doi: 10.3748/wjg.v20.i34.12039. Review.

11.

Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses.

Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A.

PLoS One. 2014 Sep 16;9(9):e107177. doi: 10.1371/journal.pone.0107177. Review.

12.

Does antiviral therapy reduce complications of cirrhosis?

Chung GE, Lee JH, Kim YJ.

World J Gastroenterol. 2014 Jun 21;20(23):7306-11. doi: 10.3748/wjg.v20.i23.7306. Review.

13.

To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy.

Mekky MA.

World J Hepatol. 2014 Apr 27;6(4):226-9. doi: 10.4254/wjh.v6.i4.226. Review.

14.

Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.

Kim HN, Rodriguez CV, Van Rompaey S, Eron JJ, Thio CL, Crane HM, Overton ET, Saag MS, Martin J, Geng E, Mugavero M, Rodriguez B, Mathews WC, Boswell S, Moore R, Kitahata MM; Centers for AIDS Research Network of Integrated Clinical Systems..

J Acquir Immune Defic Syndr. 2014 May 1;66(1):96-101. doi: 10.1097/QAI.0000000000000126.

15.
16.

A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.

Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF.

PLoS One. 2012;7(2):e32622. doi: 10.1371/journal.pone.0032622.

17.

Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.

Sherman M, Lee SS.

Can J Gastroenterol. 2011 Oct;25(10):538-41. No abstract available.

18.

Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.

Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e96-9. doi: 10.1097/QAI.0b013e3182303937. No abstract available.

19.

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ.

J Clin Oncol. 2011 Sep 20;29(27):3643-50. doi: 10.1200/JCO.2011.36.2335.

20.

Hepatitis B--more treatments, more testing, not enough data.

Fox RK.

J Gen Intern Med. 2011 Mar;26(3):232-3. doi: 10.1007/s11606-010-1626-0. No abstract available.

Items per page

Supplemental Content

Support Center